Targeted Therapies for Slow-Flow Vascular Malformations

Area of Science:

• Genetics and Molecular Biology
• Oncology
• Vascular Biology

Background:

• Genetic sequencing identifies somatic variants in vascular malformation pathogenesis.
• These variants are also implicated in cancer development.
• Targeted therapies from oncology are being explored for vascular malformations.

Purpose of the Study:

• To review current evidence on targeted therapies for slow-flow vascular malformations.
• To focus on therapies targeting the PI3K/AKT/mTOR pathway.
• To examine the role of gain-of-function variants in treatment strategies.

Main Methods:

• Literature review of genetic sequencing and targeted therapy studies.
• Analysis of evidence for PI3K/AKT/mTOR pathway inhibitors.
• Focus on slow-flow vascular malformations.

Main Results:

• Growing evidence supports targeted therapies for vascular malformations.
• Gain-of-function variants in PI3K/AKT/mTOR pathway are key targets.
• Oncology-derived therapies demonstrate efficacy in preclinical and clinical settings.

Conclusions:

• Targeted therapies, particularly those inhibiting the PI3K/AKT/mTOR pathway, offer a promising treatment avenue for vascular malformations.
• Understanding the genetic basis of these malformations is crucial for personalized treatment.
• Repurposing cancer therapies holds significant potential for improving patient outcomes.